Men with cT3 PCa may benefit from surgery

San Antonio--Urologists who might have bypassed the option of surgery to send patients with clinical T3 (cT3) disease directly to a radiation oncologist might want to rethink the way they refer patients, according to a new study.

Related Videos

Related Content

Advertisement

March 19th 2025

Real-world data reaffirm oncologic benefits of BLC for NMIBC

Hannah Clarke

"These data support current AUA/SUO guidelines recommending BLC usage in patients with NMIBC to increase detection and decrease recurrence," says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 18th 2025

FDA greenlights trial of orellanine in metastatic renal cell carcinoma

Hannah Clarke

The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.

Related Content

Advertisement

March 19th 2025

Real-world data reaffirm oncologic benefits of BLC for NMIBC

Hannah Clarke

"These data support current AUA/SUO guidelines recommending BLC usage in patients with NMIBC to increase detection and decrease recurrence," says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 18th 2025

FDA greenlights trial of orellanine in metastatic renal cell carcinoma

Hannah Clarke

The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.

March 17th 2025

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer

Michael R. Folkert, MD, PhD Benjamin P. Saylor

"4 years following radiation therapy, there is a 25% lower hazard of bowel disorders and a 46% lower hazard of related procedures [in patients who received a spacer],” says Michael R. Folkert, MD, PhD.